{"protocolSection":{"identificationModule":{"nctId":"NCT00645853","orgStudyIdInfo":{"id":"D1250C00042"},"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Long-term Safety in Atrial Fibrillation Patients","officialTitle":"Long-term Treatment With the Oral Direct Thrombin Inhibitor AZD0837, Compared to Vitamin-K Antagonists, as Stroke Prevention in Patients With Non-valvular Atrial Fibrillation and One or More Risk Factors for Stroke and Systemic Embolic Events. A 5-year Follow-up Study"},"statusModule":{"statusVerifiedDate":"2012-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-10"},"primaryCompletionDateStruct":{"date":"2009-05","type":"ACTUAL"},"completionDateStruct":{"date":"2009-05","type":"ACTUAL"},"studyFirstSubmitDate":"2008-03-19","studyFirstSubmitQcDate":"2008-03-25","studyFirstPostDateStruct":{"date":"2008-03-28","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-06-30","resultsFirstSubmitQcDate":"2012-02-02","resultsFirstPostDateStruct":{"date":"2012-03-06","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-03-20","lastUpdatePostDateStruct":{"date":"2012-03-23","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to provide safety and tolerability data for AZD0837 during long-term treatment (5 years) in patients with non-valvular atrial fibrillation (AF) and one or more additional risk factors for stroke and systemic embolic events (moderate to high risk patients)."},"conditionsModule":{"conditions":["Persistent or Permanent Nonvalvular Atrial Fibrillation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":523,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: AZD0837"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: VKA INR 2-3"]}],"interventions":[{"type":"DRUG","name":"AZD0837","description":"Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od","armGroupLabels":["1"]},{"type":"DRUG","name":"VKA INR 2-3","description":"Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5","armGroupLabels":["2"],"otherNames":["warfarin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Bleeding: Number of Patients With Any Bleeding Event, During Treatment Period","description":"Participants","timeFrame":"154-711 days on treatment"}],"secondaryOutcomes":[{"measure":"Alanine Transaminase (ALAT): Number of Patients With ALAT>=3xULN, Post Baseline","description":"ULN=Upper limit of Normal","timeFrame":"From baseline to Follow up"},{"measure":"Bilirubin: Number of Patients With Bilirubin>=2xULN, Post Baseline","timeFrame":"From baseline to Follow up"},{"measure":"Creatinine: Absolute Change From Baseline, at End of Treatment","timeFrame":"Baseline and End of treatment"},{"measure":"D-dimer:Median and Quartile Range at End of Treatment","description":"Median (Lower Quartile-Upper Quartile ), ng/mL","timeFrame":"End of treatment"},{"measure":"Activated Partial Thromboplastin Time (APTT): Absolute Change From Baseline to End of Treatment","description":"Median Full range, Seconds","timeFrame":"Baseline and End of treatment"},{"measure":"Electroconvulsive Therapy (ECT): Absolute Change From Baseline to End of Treatment","timeFrame":"Baseline and End of Treatment"},{"measure":"AZD0837: Plasma Concentration of AZD0837 at End of Treatment","timeFrame":"End of treatment"},{"measure":"AR-H067637XX, the Active Major Metabolite of AD0837: Plasma Concentration of AR-H067637XX, at End of Treatment","timeFrame":"154-711 days on treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with paroxysmal, persistent or permanent Non Valvular Atrial Fibrillation with one or more additional risk factors for stroke and systemic embolic event\n* completing treatment with study drug in D1250C00008.\n\nExclusion Criteria:\n\n* Atrial Fibrillation secondary to reversible disorders, eg hyperthyroidism\n* Presence of a valvular heart disease, mechanical heart valves, active endocarditis, left ventricular aneurysm or thrombus, atrial myxoma or any condition other than Atrial Fibrillation requiring chronic anticoagulation treatment\n* Myocardial infarction, heart surgery or percutaneous coronary intervention (PCI) within the previous three months prior to inclusion; Stroke and/or systemic embolism within the previous 30 days prior to inclusion\n* Conditions associated with increased risk of major bleeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Lars Hvilstedt Rasmussen, MD, PhD, FESC","affiliation":"Head of Cardiology at Heart Centre Aalborg Aarhus University Hospital DK 9100 Aalborg Denmark","role":"PRINCIPAL_INVESTIGATOR"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"All participants had previously participated in the Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation (NCT00684307) study","recruitmentDetails":"The study population included male and female participants \\>18 years of age with chronic non-valvular Atrial Fibrillation. The participants were recruited during the time period from 25 October 2007 to 20 May 2008 at medical clinics in Europe.","groups":[{"id":"FG000","title":"AZD0837","description":"Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od."},{"id":"FG001","title":"VKA, INR 2-3","description":"Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"288"},{"groupId":"FG001","numSubjects":"235"}]},{"type":"No of Patients After Dose Switch","achievements":[{"groupId":"FG000","comment":"All patients in the AZD0837 arm switched from their initial doses, to a general dose of 300 mg od","numSubjects":"209"},{"groupId":"FG001","comment":"No changes for VKA patients","numSubjects":"188"}]},{"type":"Discontinued Patient No Due to Closure","achievements":[{"groupId":"FG000","comment":"No of patients discontinued due the study termination caused tablet formulation stability problems","numSubjects":"196"},{"groupId":"FG001","comment":"No of patients discontinued due the study termination caused tablet formulation stability problems","numSubjects":"178"}]},{"type":"AZ Study Closure in Hungary","achievements":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"40"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"196"},{"groupId":"FG001","numSubjects":"178"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"92"},{"groupId":"FG001","numSubjects":"57"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"AZ study closure in Hungary","reasons":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"40"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Discontinuation criteria","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"recall of ICF, planned operation, death","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"AZD0837","description":"Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od."},{"id":"BG001","title":"VKA, INR 2-3","description":"Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"288"},{"groupId":"BG001","value":"235"},{"groupId":"BG002","value":"523"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"FULL_RANGE","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69.9","lowerLimit":"34","upperLimit":"93"},{"groupId":"BG001","value":"68.0","lowerLimit":"33","upperLimit":"86"},{"groupId":"BG002","value":"68.95","lowerLimit":"33","upperLimit":"93"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"90"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"163"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"198"},{"groupId":"BG001","value":"162"},{"groupId":"BG002","value":"360"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Bleeding: Number of Patients With Any Bleeding Event, During Treatment Period","description":"Participants","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"154-711 days on treatment","groups":[{"id":"OG000","title":"AZD0837","description":"Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od."},{"id":"OG001","title":"VKA, INR 2-3","description":"Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"288"},{"groupId":"OG001","value":"235"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"56"}]}]}]},{"type":"SECONDARY","title":"Alanine Transaminase (ALAT): Number of Patients With ALAT>=3xULN, Post Baseline","description":"ULN=Upper limit of Normal","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From baseline to Follow up","groups":[{"id":"OG000","title":"AZD0837","description":"Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od."},{"id":"OG001","title":"VKA, INR 2-3","description":"Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"288"},{"groupId":"OG001","value":"235"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"}]}]}]},{"type":"SECONDARY","title":"Bilirubin: Number of Patients With Bilirubin>=2xULN, Post Baseline","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From baseline to Follow up","groups":[{"id":"OG000","title":"AZD0837","description":"Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od."},{"id":"OG001","title":"VKA, INR 2-3","description":"Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"288"},{"groupId":"OG001","value":"235"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"SECONDARY","title":"Creatinine: Absolute Change From Baseline, at End of Treatment","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"µmol/L","timeFrame":"Baseline and End of treatment","groups":[{"id":"OG000","title":"AZD0837","description":"Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od."},{"id":"OG001","title":"VKA, INR 2-3","description":"Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"288"},{"groupId":"OG001","value":"235"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.70","spread":"-67.0","lowerLimit":"-67.0","upperLimit":"120.0"},{"groupId":"OG001","value":"-1.17","spread":"-56.0","lowerLimit":"-56.0","upperLimit":"116"}]}]}]},{"type":"SECONDARY","title":"D-dimer:Median and Quartile Range at End of Treatment","description":"Median (Lower Quartile-Upper Quartile ), ng/mL","populationDescription":"Only patients who switched to one common dose, 300 mg od, are included in the AZD0837 analysis","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"ng/mL","timeFrame":"End of treatment","groups":[{"id":"OG000","title":"AZD0837","description":"Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od."},{"id":"OG001","title":"VKA, INR 2-3","description":"Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"232"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.9","lowerLimit":"43.3","upperLimit":"128.4"},{"groupId":"OG001","value":"54.9","lowerLimit":"31.9","upperLimit":"99.0"}]}]}]},{"type":"SECONDARY","title":"Activated Partial Thromboplastin Time (APTT): Absolute Change From Baseline to End of Treatment","description":"Median Full range, Seconds","populationDescription":"Only patients who switched to one common dose, 300 mg od, are included in the AZD0837 analysis","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"sec","timeFrame":"Baseline and End of treatment","groups":[{"id":"OG000","title":"AZD0837","description":"Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"173"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","lowerLimit":"-62","upperLimit":"43"}]}]}]},{"type":"SECONDARY","title":"Electroconvulsive Therapy (ECT): Absolute Change From Baseline to End of Treatment","populationDescription":"Only patients who switched to one dose, 300 mg od, are included in the AZD0837 analysis","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"sec","timeFrame":"Baseline and End of Treatment","groups":[{"id":"OG000","title":"AZD0837","description":"Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"129"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0","lowerLimit":"-5","upperLimit":"96"}]}]}]},{"type":"SECONDARY","title":"AZD0837: Plasma Concentration of AZD0837 at End of Treatment","populationDescription":"Only patients who switched to one dose, 300 mg od, are included in the AZD0837 analysis","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"nmol/L","timeFrame":"End of treatment","groups":[{"id":"OG000","title":"AZD0837","description":"Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"675","lowerLimit":"10","upperLimit":"4090"}]}]}]},{"type":"SECONDARY","title":"AR-H067637XX, the Active Major Metabolite of AD0837: Plasma Concentration of AR-H067637XX, at End of Treatment","populationDescription":"Only patients who switched to one dose, 300 mg od, are included in the AZD0837 analysis","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"nmol/L","timeFrame":"154-711 days on treatment","groups":[{"id":"OG000","title":"AZD0837","description":"Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"341","lowerLimit":"10","upperLimit":"929"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"154-711 days on treatment","eventGroups":[{"id":"EG000","title":"AZD0837","description":"Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od","seriousNumAffected":73,"seriousNumAtRisk":288,"otherNumAffected":125,"otherNumAtRisk":288},{"id":"EG001","title":"VKA INR 2-3","description":"Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5","seriousNumAffected":61,"seriousNumAtRisk":235,"otherNumAffected":106,"otherNumAtRisk":235}],"seriousEvents":[{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Cardiac Failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":288},{"groupId":"EG001","numAffected":6,"numAtRisk":235}]},{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":288},{"groupId":"EG001","numAffected":4,"numAtRisk":235}]},{"term":"Angina Unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":3,"numAtRisk":235}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":288},{"groupId":"EG001","numAffected":2,"numAtRisk":235}]},{"term":"Angina Pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Sick Sinus Syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Acute Coronary Syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Atrial Flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Bradyarrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Cardiac Failure Congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Chordae Tendinae Rupture","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Coronary Artery Stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Heart Valve Incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Myocardial Ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Tachyarrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Ventricular Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":2,"numAtRisk":235}]},{"term":"Eye Haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Retinal Artery Embolism","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Gastrointestinal Haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":3,"numAtRisk":235}]},{"term":"Gastric Ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":2,"numAtRisk":235}]},{"term":"Abdominal Hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Abdominal Pain Lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Anal Haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Anal Ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Inguinal Hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Periodontal Disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Non-Cardiac Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":2,"numAtRisk":235}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Cholecystitis Chronic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Jaundice Cholestatic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Corneal Graft Rejection","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":288},{"groupId":"EG001","numAffected":3,"numAtRisk":235}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":288},{"groupId":"EG001","numAffected":3,"numAtRisk":235}]},{"term":"Abscess Limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Endocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Intervertebral Discitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Foreign Body Trauma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Head Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Joint Dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Post Procedural Haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Subdural Haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Tibia Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Alanine Aminotransferase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Haemoglobin Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":2,"numAtRisk":235}]},{"term":"Blood Alkaline Phosphatase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Blood Glucose Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"International Normalised Ratio Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Diabetes Mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":2,"numAtRisk":235}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Bursitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Inguinal Mass","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Muscle Atrophy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Muscular Weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Osteitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Rheumatoid Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Scleroderma","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Colon Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Basal Cell Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Colon Adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Colon Cancer Metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Metastases To Central Nervous System","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":2,"numAtRisk":235}]},{"term":"Transient Ischaemic Attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":2,"numAtRisk":235}]},{"term":"Cerebral Artery Embolism","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Cerebrovascular Accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Encephalitis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Ischaemic Stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Status Epilepticus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Vascular Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Vertebrobasilar Insufficiency","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Delusional Disorder, Persecutory Type","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Dysthymic Disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Renal Failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Urinary Bladder Haemorrhage","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Postmenopausal Haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Dyspnoea Exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Pleural Effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Arterial Occlusive Disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Arterial Stenosis Limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Orthostatic Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Peripheral Artery Aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Peripheral Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"Subclavian Vein Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]},{"term":"800003Varicose Vein","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":235}]}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":288},{"groupId":"EG001","numAffected":18,"numAtRisk":235}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":288},{"groupId":"EG001","numAffected":1,"numAtRisk":235}]},{"term":"Oedema Peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":288},{"groupId":"EG001","numAffected":20,"numAtRisk":235}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":288},{"groupId":"EG001","numAffected":9,"numAtRisk":235}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":35,"numAtRisk":288},{"groupId":"EG001","numAffected":30,"numAtRisk":235}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":288},{"groupId":"EG001","numAffected":18,"numAtRisk":235}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":288},{"groupId":"EG001","numAffected":15,"numAtRisk":235}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":288},{"groupId":"EG001","numAffected":12,"numAtRisk":235}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":288},{"groupId":"EG001","numAffected":12,"numAtRisk":235}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":288},{"groupId":"EG001","numAffected":13,"numAtRisk":235}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":288},{"groupId":"EG001","numAffected":17,"numAtRisk":235}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Gerard Lynch","organization":"AstraZeneca","email":"aztrial_results_posting@astrazeneca.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000014859","term":"Warfarin"}],"ancestors":[{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M17245","name":"Vitamin K","relevance":"LOW"},{"id":"M17248","name":"Vitamins","relevance":"LOW"},{"id":"M16366","name":"Thrombin","relevance":"LOW"},{"id":"M17292","name":"Warfarin","asFound":"Third","relevance":"HIGH"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T481","name":"Vitamin K","relevance":"LOW"},{"id":"T450","name":"Menaquinone","relevance":"LOW"},{"id":"T449","name":"Menadione","relevance":"LOW"},{"id":"T452","name":"Naphthoquinone","relevance":"LOW"},{"id":"T458","name":"Phylloquinone","relevance":"LOW"}],"browseBranches":[{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Vi","name":"Vitamins"}]}},"hasResults":true}